Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 17/20 | 0.44 |
| ▸ | KLRK1 | P26718 | 2/20 | 0.40 |
| ▸ | MICA | Q29983 | 2/20 | 0.40 |
| ▸ | RAET1L | Q5VY80 | 2/20 | 0.40 |
| ▸ | APOB | P04114 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3737499 | 0.96 | MTTP (0.42) | MTTPKLRK1MICARAET1LAPOB | |
| SCHEMBL14031595 | 0.96 | MTTP (0.43) | MTTPKLRK1MICARAET1LAPOB | |
| SCHEMBL3722379 | 0.95 | KLRK1 (0.44) | MTTPKLRK1MICARAET1LAPOB | |
| SCHEMBL3726226 | 0.95 | MTTP (0.39) | MTTPKLRK1MICARAET1L | |
| SCHEMBL3726156 | 0.95 | MTTP (0.43) | MTTPKLRK1MICARAET1LAPOB | |
| SCHEMBL3726036 | 0.94 | MTTP (0.41) | MTTPKLRK1MICARAET1LAPOB | |
| SCHEMBL3727097 | 0.94 | MTTP (0.44) | MTTPAPOB | |
| SCHEMBL3723799 | 0.94 | MTTP (0.45) | MTTPKLRK1MICARAET1L | |
| SCHEMBL3730523 | 0.94 | MTTP (0.39) | MTTPKLRK1MICARAET1LAPOB | |
| SCHEMBL3726127 | 0.94 | MTTP (0.46) | MTTPKLRK1MICARAET1LAPOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 283 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321073-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | Response IP Holding Company, LLC (US) | 2023-10-12 | — | — | US | claimed |
| CN-116710083-A | Compositions and methods for treating metabolic disorders | 反应IP控股有限责任公司 | 2023-09-05 | — | — | CN | claimed |
| EP-4192579-A2 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | Response IP Holding Company, LLC (US) | 2023-06-14 | — | — | EP | claimed |
| WO-2023101441-A1 | USE OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR IN TREATMENT OF FIBROSIS DISEASE | 에스케이케미칼 주식회사 | 2023-06-08 | — | — | WO | claimed |
| WO-2022032077-A2 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | REDUX THERAPEUTICS, LLC (US) | 2022-02-10 | — | — | WO | claimed |
| US-20100158996-A1 | ESTER COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. | 2010-06-24 | — | — | US | claimed |
| US-7625948-B2 | Ester compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2009-12-01 | — | — | US | claimed |
| US-20060153913-A1 | Solid formulation with improved solubility and stability, and method for producing said formulation | JAPAN TOBACCO INC. (JP) | 2006-07-13 | — | — | US | claimed |
| US-20050075367-A1 | Ester compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-04-07 | — | — | US | claimed |
| EP-1479666-A1 | ESTER COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-11-24 | — | — | EP | claimed |
| CN-116710439-B | Substituted pyrazolopiperidine carboxylic acids | BAYER AG (DE) | 2026-05-26 | — | — | CN | disclosed |
| CN-116829545-B | Substituted pyrazolylpiperidine carboxylic acids | 拜耳公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12595247-B2 | Substituted pyrazolo piperidine carboxylic acids | BAYER AKTIENGESELLSCHAFT (DE) | 2026-04-07 | — | — | US | disclosed |
| EP-3558298-B1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12540134-B2 | Inhibitors of adrenoreceptor ADRAC2 | BAYER AKTIENGESELLSCHAFT (DE) | 2026-02-03 | — | — | US | disclosed |
| EP-1769793-A1 | THERAPEUTIC OR PREVENTIVE DRUG FOR DIABETES, OBESITY, OR ARTERIOSCLEROSIS | Japan Tobacco, Inc. (JP) | 2007-04-04 | — | — | EP | disclosed |
| US-20060153913-A1 | Solid formulation with improved solubility and stability, and method for producing said formulation | JAPAN TOBACCO INC. (JP) | 2006-07-13 | — | — | US | disclosed |
| US-20060030623-A1 | Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis | JAPAN TOBACCO INC. (JP) | 2006-02-09 | — | — | US | disclosed |
| US-20050075367-A1 | Ester compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-04-07 | — | — | US | disclosed |
| EP-1479666-A1 | ESTER COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075367-A1 | Ester compound and medicinal use thereof | LIPC, CES1, MTTP | MTTP 3/4885KLRK1 3360/4885MICA 3630/4885 |
| US-12540134-B2 | Inhibitors of adrenoreceptor ADRAC2 | ADRA2C, ADRB3, ADRB2 | MTTP 2650/4885KLRK1 4345/4885MICA 3268/4885 |
| US-20100158996-A1 | ESTER COMPOUND AND MEDICAL USE THEREOF | LIPC, CES1, MTTP | MTTP 3/4885KLRK1 3855/4885MICA 3640/4885 |
| US-20230321073-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | LIPC, CPT1A, CETP | MTTP 5/4885KLRK1 4368/4885MICA 2740/4885 |
| US-12595247-B2 | Substituted pyrazolo piperidine carboxylic acids | SSB, PDK4, FPR1 | MTTP 4650/4885KLRK1 3335/4885MICA 4495/4885 |
| US-20060030623-A1 | Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis | FABP4, GPR119, SLC5A1 | MTTP 889/4885KLRK1 4726/4885MICA 3618/4885 |
| US-20060153913-A1 | Solid formulation with improved solubility and stability, and method for producing said formulation | ABCG2, SORD, SRI | MTTP 1276/4885KLRK1 1076/4885MICA 4257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.